Contribution of nutritional support to treatment neuromuscular impairmets of critically ill patients;Contribución del soporte nutricional al tratamiento de las alteraciones neuro-musculares del paciente crítico

Nutricion Hospitalaria

Volumn 21, Issue SUPPL. 3, 2006, Pages 118-122

  Montejo Gonzalez J C ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Critically ill patient; Glutamine; Hyperglycemia; Hypophosphatemia; Myopathy; Polyneuropathy

Indexed keywords

GLUTAMINE;

CRITICALLY ILL PATIENT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; METABOLISM; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; MYOPATHY; NEUROMUSCULAR DISEASE; NEUROMUSCULAR FUNCTION; NUTRITIONAL SUPPORT; POLYNEUROPATHY; REVIEW; SEPSIS; STRESS;

CRITICAL ILLNESS; GLUTAMINE; HUMANS; MUSCULAR DISEASES; NUTRITIONAL SUPPORT; POLYNEUROPATHIES;

EID: 33745080870     PISSN: 02121611     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Bolton CF: Neuromuscular manifestations of critical illness. Muscle Nerve 2005; 32:140-63.
2. Lacomis D, Zochodne DW, Bird SJ: Critical illness myopathy. Muscle Nerve 2000; 23:1785-1788.
3. Witt NJ, Zochodne DW, Bolton CF y cols.: Peripheral nerve function in sepsis and multiple organ failure. Chest 1991; 99:176-184.
4. Bolton C, Brown J, Sibbald W: The electrophysiologic investigation of respiratory paralysis in critically ill patients. Neurology 1983; 33:186.
5. Marino PL, Millili JJ: Possible role of dietary lipids in critical illness polyneuropathy. Intensive Care Med 1998; 24:87.
6. Waldhausen E, Mingers B, Lippers P, Keser G: Critical illness polyneuropathy due to parenteral nutrition. Intensive Care Med 1997; 23:922-923.
7. Garnacho-Montero J, Madrazo-Osuna J, García-Garmendía JL y cols.: Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med 2001; 27:1288-96.
8. Bolton CF, Young GB: Critical illness polyneuropathy due to parenteral nutrition. Intensive Care Med 1997; 23:924-925.
9. Leijten FS, de Weerd AW: Letter to the Editor. N Engl J Med 1990; 323:1631.
10. van den Berghe G, Wouters P, Weekers F y cols.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-67.
11. Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ: Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005; 64:1348-53.
12. Mesotten D, Wouters PJ, Peeters RP y cols.: Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness. J Clin Endocrinol Metab 2004; 89:3105-13.
13. Burnham EL, Moss M, Ziegler TR: Myopathies in critical illness: characterization and nutritional aspects. J Nutr 2005; 135:1818S-1823S.
14. Jeejeebhoy KN: Muscle function and energetics. En: Wilmore DW, Carpentier YA (Eds) Metabolic support of the critically ill patient. Springer Verlag. Berlin 1993:44-62.
15. Ortiz Leyba C, Gómez Tello V, Serón Arbeloa C: Requerimientos de macronutrientes y micronutrientes. Nutr Hosp 2005; 20:13-17.
16. Wolfe RR: Optimal nutrition, exercise, and hormonal therapy promote muscle anabolism in the elderly. J Am Coll Surg 2006; 202:176-80.
17. Shizgal HM, Vasilevsky CA, Gardiner PF et al.: Nutritional assessment and skeletal function. Am J Clin Nutr 1986; 44:761-777.
18. Legaspi A, Roberts JP, Albert JD, Tracey KJ, Shires GT, Lowry SF: The effect of starvation and total parenteral nutrition on skeletal muscle amino acid content and membrane potential difference in normal man. Surg Gynecol Obstet 1988; 166:233-40.
19. Hammarqvist F, Andersson K, Luo JL, Wernerman J: Free amino acid and glutathione concentrations in muscle during short-term starvation and refeeding. Clin Nutr 2005; 24:236-43.
20. Kraft MD, Btaiche IF, Sacks GS: Review of the refeeding syndrome. Nutr Clin Pract 2005; 20:625-33.
21. th edition. Lea & Febiger. Philadelphia. 1994:1207-1240.
22. Smith JL. Artega C. Heymsfield S: Regulation of protein degradation in differentiated skeletal muscle cells in monolayer culture. En: Khairallah E, Bond J, Bird JC (eds). Intracellular protein catabolism. New York. Liss. 1985
23. Souba WW. Herskowitz K. Salloum Rh. et al.: Gut glutamine metabolism. JPEN 1990; 14 (S):45-50.
24. Kinney JM: Clinical biochemistry: Implications for nutritional support. JPEN 1990; 14 (S):148-156.
25. Gamrin L, Essen P, Forsberg AM, Hultman E, Wernerman J: A descriptive study of skeletal muscle metabolism in critically ill patients: free amino acids, energy-rich phosphates, protein, nucleic acids, fat, water, and electrolytes. Crit Care Med 1996; 24:575-583.
26. Roth E, Karner J, Ollenschläger G y cols.: Alanylglutamine reduces muscle loss of alanine and glutamine in postoperative anaesthetized dogs. Clin Sci 1988; 75:641-648.
27. Karner J, Roth E, Ollenschlager G y cols.: Glutamine-containing dipeptides as infusion substrates in the septic state. Surgery 1989; 106:893-900.
28. Novak F, Heyland DK, Avenell A, Drover JW, Su X: Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med 2002; 30:2022-9.
29. Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P: Canadian Critical Care Clinical Practice Guidelines Committee. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 2003; 27:355-73.
30. Skeie B, Kvetan V, Gil KM, Rothkopf MM, Newsholme EA, Askanazi J: Branch-chain amino acids: their metabolism and clinical utility. Crit Care Med 1990; 18:549-571.
31. Jiménez J. Ortiz C. Morales S. et al: Prospective study on the efficacy of branched-chain amino acids in septic patients. JPEN 1991; 15:252-261.
32. Jiménez J. Ortiz C. Morales S. et al.: Variations in plasma amino acids in septic patients subjected to parenteral nutrition with a high proportion of branched-chain amino acids. Nutrition 1992; 8:237-244.
33. García de Lorenzo A, Ortiz-Leyba C, Planas M y cols.: Parenteral administration of different amounts of branch-chain amino acids in septic patients: clinical and metabolic aspects. Crit Care Med 1997; 25:418-24.
34. Barua JM, Wilson E, Downie S y cols.: The effect of alanyl-glutamine peptide supplementation on muscle protein synthesis in post-surgical patients receiving glutamine-free aminoacids intravenously. Proc Nutr Soc 1992; 51:104A.
35. Stehle P, Zander J, Mertes N y cols.: Effect of parenteral glutamine peptide supplements on muscle glutamine loss and nitrogen balance after major surgery. Lancet 1989; i:231-233
36. Hammarqvist F, Wernerman J, Von der Decken A, Vinnars E: Alanyl-glutamine counteracts the depletion of free glutamine and the postoperative decline in protein synthesis in skeletal muscle. Ann Surg 1990; 212:637-644.
37. Roth E, Karner J, Ollenschlager G: Glutamine: an anabolic effector? JPEN J Parenter Enteral Nutr 1990; 14:130S-136S.
38. Gamrin L, Essen P, Hultman E, Wernerman J: Muscle energy status in critically ill patients supplemented with glutamine/alphaketoglutarate. Clin Nutr 1993; 12 (Suppl 2):17.
39. Palmer TE, Griffiths RD, Jones C: Effect of parenteral L-glutamine on muscle in the very severely ill. Nutrition 1996; 12:316-20.
40. Furst P. Sthele P: The potential use of parenteral dipeptides in clinical nutrition. NCP 1993; 8:106-114.
41. Tjader I, Rooyackers O, Forsberg AM, Vesali RF, Garlick PJ, Wernerman J: Effects on skeletal muscle of intravenous glutamine supplementation to ICU patients. Intensive Care Med 2004; 30:266-75.
42. Carroll PV, Jackson NC, Russell-Jones DL, Treacher DF, Sonksen PH, Umpleby AM: Combined growth hormone/insulin-like growth factor I in addition to glutamine-supplemented TPN results in net protein anabolism in critical illness. Am J Physiol Endocrinol Metab 2004; 286:E151-7.
43. Takala J, Ruokonen E, Webster NR, Neilsen MS, Zandstra DF,Vundelinckx G, Hinds CJ: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341:785-792, 1999.